Sana Biotechnology Inc
$ 3.93
10.70%
06 Feb - close price
- Market Cap 1,046,819,000 USD
- Current Price $ 3.93
- High / Low $ 4.00 / 3.68
- Stock P/E N/A
- Book Value 0.74
- EPS -0.96
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.96 %
- 52 Week High 6.55
- 52 Week Low 1.26
About
Sana Biotechnology Inc., based in Seattle, Washington, is at the forefront of biotherapeutic innovation, specializing in engineered cell therapies that address significant unmet medical needs across a range of diseases. Leveraging its state-of-the-art cell-engineering platform, the company is making strides in gene therapy and regenerative medicine with a robust pipeline that reflects its commitment to transforming patient care. With strong research and development capabilities, Sana presents a compelling opportunity for institutional investors seeking exposure to groundbreaking advancements in the biopharmaceutical sector.
Analyst Target Price
$8.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-11 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-03 | 2023-05-08 | 2023-03-16 |
| Reported EPS | -0.16 | -0.39 | -0.2 | -0.23 | -0.25 | -0.32 | -0.32 | -0.41 | 0.02 | -0.59 | -0.43 | -0.38 |
| Estimated EPS | -0.18 | -0.2 | -0.2 | -0.2428 | -0.27 | -0.28 | -0.32 | -0.38 | -0.45 | -0.43 | -0.45 | -0.51 |
| Surprise | 0.02 | -0.19 | 0 | 0.0128 | 0.02 | -0.04 | 0 | -0.03 | 0.47 | -0.16 | 0.02 | 0.13 |
| Surprise Percentage | 11.1111% | -95% | 0% | 5.2718% | 7.4074% | -14.2857% | 0% | -7.8947% | 104.4444% | -37.2093% | 4.4444% | 25.4902% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2026-02-04 19:30:42
Investors looking at Sana Biotechnology Inc (SANA) shares, currently priced at $4.17, might consider a put option strategy. Selling a January 2028 put contract at a $2.50 strike price for 65 cents offers a 26% return on the commitment, or a 13.2% annualized rate. This strategy allows investors to potentially acquire shares at a lower cost basis if the stock drops significantly, while otherwise collecting the premium.
2026-02-02 22:28:58
Sana Biotechnology, Inc. (NASDAQ:SANA) has received a consensus "Moderate Buy" rating from ten analysts, with an average one-year price target of $8.14. The company, which opened at $4.43 and has a market capitalization of $1.18 billion, remains unprofitable but recently beat its quarterly EPS estimate. Institutional investors hold a significant portion of the stock, with several large firms increasing their positions.
2026-01-30 22:30:44
Sana Biotechnology, Inc. (SANA) is attracting investor attention with a potential upside of 89.44%, driven by its innovative engineered cell medicines for type 1 diabetes and autoimmune diseases. Despite being in the R&D phase with no revenue and negative financials, analysts are optimistic due to its promising product pipeline. The company's strategic partnerships and ongoing clinical trials for candidates like UP421 and SC291 position it as a high-risk, high-reward opportunity in the biotechnology sector.
2026-01-25 08:58:28
Baillie Gifford & Co. has increased its stake in Sana Biotechnology (NASDAQ:SANA) by 13.6%, bringing their total to 11,436,503 shares, representing a 4.81% stake valued at approximately $40.6 million. Institutional investors now own 88.23% of the company, and analysts have a "Moderate Buy" rating with a consensus price target of $8.14. Sana Biotechnology also slightly exceeded its last quarter's EPS estimates.
2026-01-23 09:55:00
Wall Street analysts project Sana Biotechnology (SANA) could see a 74.2% upside, with a mean target of $8.71. Despite the optimism, the article cautions against solely relying on price targets, highlighting their frequent inaccuracy and potential for bias. However, the strong agreement among analysts in revising EPS estimates higher and SANA's Zacks Rank #2 (Buy) status suggest potential near-term upside for the stock.
2026-01-18 01:58:09
Flagship Pioneering and Quotient Therapeutics have announced the appointment of Rahul Kakkar, M.D., as CEO-Partner at Flagship and Chief Executive Officer of Quotient Therapeutics. Dr. Kakkar brings nearly two decades of experience in founding and building biotechnology companies, including CEO roles at Tome Biosciences and Pandion Therapeutics, and co-founding Corvidia Therapeutics. He will lead Quotient in advancing its Somatic Genomics platform for discovering novel drug targets.
